Dr. Markowski discusses novel agent VERU-111 in mCRPC

Urology Times staff

Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer (mCRPC) being presented during the 2021 ASCO Annual Meeting. Markowski, the lead study author and assistant professor of oncology at Johns Hopkins Medicine, also comments on where VERU-111 might fit in the mCRPC treatment sequence. (J Clin Oncol 39, 2021 [suppl 15; abstr 5056]. doi: 10.1200/JCO.2021.39.15_suppl.5056)